What is Daye?
Daye operates at the intersection of sustainable consumer goods and medical science. Headquartered in London, the company provides a subscription-based model for organic, sustainable period care products, including CBD-infused options. Beyond its consumer-facing offerings, Daye has distinguished itself through the development of ProViotics, a specialized probiotic solution designed to support vaginal health. The company's market position is further bolstered by its active investment in clinical research, specifically targeting the historical underrepresentation of women in medical studies. This dual-pronged approach—combining high-quality, eco-conscious products with rigorous scientific inquiry—positions Daye as a leader in the evolving femtech landscape.
How much funding has Daye raised?
Daye has raised a total of $11.5M across 1 funding round:
Series A
$11.5M
Series A (2022): $11.5M with participation from Hambro Perks, MassMutual Ventures, and Cross-Border Impact Ventures
Key Investors in Daye
Hambro Perks
Hambro Perks is a London-headquartered international investment firm focused on private technology investing, supporting growth businesses across various stages of the investment cycle.
Cross-Border Impact Ventures
Cross-Border Impact Ventures is an impact venture capital firm dedicated to transformative health technology companies, with a specific focus on women, children, and adolescent health.
MassMutual Ventures
MassMutual Ventures is a multi-stage venture capital firm that invests in financial technology, enterprise software, and digital health companies to drive long-term value.
What's next for Daye?
With the infusion of $11.5M, Daye is poised to deepen its research and development capabilities, particularly regarding its ProViotics line and future medical device innovations. The company's strategic roadmap involves scaling its subscription infrastructure while simultaneously advocating for gender health equality through data-driven research initiatives. As the firm moves beyond its Series A milestone, the focus will likely shift toward international market penetration and the commercialization of new diagnostic tools. By leveraging its existing partnerships with impact-focused investors, Daye aims to bridge the gap between consumer wellness and clinical-grade healthcare, setting a new standard for the industry.
See full Daye company page
